RedHill Biopharma Faces Nasdaq Delisting Risk
Ticker: RDHL · Form: 6-K · Filed: Apr 17, 2025 · CIK: 1553846
| Field | Detail |
|---|---|
| Company | Redhill Biopharma Ltd. (RDHL) |
| Form Type | 6-K |
| Filed Date | Apr 17, 2025 |
| Risk Level | medium |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting-risk, compliance, sec-filing
Related Tickers: RHBP
TL;DR
RHBP got a Nasdaq warning for low equity, needs to fix it by Oct 14 or get booted.
AI Summary
RedHill Biopharma Ltd. received a notification from Nasdaq on April 17, 2025, indicating a deficiency in its minimum stockholders' equity. The company is required to regain compliance with Nasdaq's Listing Rule 5550(b)(1) within 180 days, by October 14, 2025, to avoid delisting.
Why It Matters
This notification puts RedHill Biopharma's listing on the Nasdaq exchange at risk, which could impact its ability to raise capital and its stock's liquidity.
Risk Assessment
Risk Level: medium — The company faces a potential delisting from Nasdaq if it cannot meet the minimum stockholders' equity requirement within the specified timeframe.
Key Numbers
- 180 days — Compliance Period (Timeframe to regain minimum stockholders' equity)
Key Players & Entities
- RedHill Biopharma Ltd. (company) — Registrant
- Nasdaq (company) — Exchange where listed
- April 17, 2025 (date) — Date of notification
- October 14, 2025 (date) — Deadline for compliance
FAQ
What specific Nasdaq rule has RedHill Biopharma failed to meet?
RedHill Biopharma has failed to meet Nasdaq's Listing Rule 5550(b)(1) regarding minimum stockholders' equity.
What is the deadline for RedHill Biopharma to regain compliance?
The company must regain compliance by October 14, 2025.
What is the consequence if RedHill Biopharma fails to regain compliance?
Failure to regain compliance could result in the delisting of RedHill Biopharma's securities from the Nasdaq exchange.
What is the company's principal executive office address?
The company's principal executive offices are located at 21 Ha'arba'a Street, Tel Aviv, 6473921, Israel.
What type of report is this filing?
This filing is a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 17, 2025 regarding RedHill Biopharma Ltd. (RDHL).